|
Gender [No. (%)]
|
|
Male
|
215(64.0)
|
|
Female
|
121(36.0)
|
|
Age [years]
|
|
< =14
|
223(66.4)
|
|
> 14
|
113(33.6)
|
|
Median (range)
|
12 (2–55)
|
|
Body weight(kg)median(range)
|
37(10–82)
|
|
Disease [No. (%)]
|
|
AML
|
110(32.7)
|
|
ALL
|
177(52.7)
|
|
CML
|
16(4.8)
|
|
MDS
|
22(6.5)
|
|
Others
|
11(3.3)
|
|
State of disease [No. (%)]
|
|
CR or Chronic phase
|
257(76.5)
|
|
NR or Advanced phase
|
79(23.5)
|
|
HLA match (low-resolution) [No. (%)]
|
|
4/6
|
113(33.6)
|
|
5/6
|
168(50.0)
|
|
6/6
|
55(16.4)
|
|
Conditioning regimen [No. (%)]
|
|
Including TBI
|
109(32.4)
|
|
Not including TBI
|
227(67.6)
|
|
Total nucleated-cell dose, 107/kg median(range)
|
4.17(1.71–13.90)
|
|
Total CD34+ cell dose, 105/kg median(range)
|
2.32(0.40–10.55)
|
